文献速递青光眼

全球青光眼药物、激光小梁成形术与小梁切除术的价格比较

A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

该横断面观察性研究纳入38个国家,比较青光眼局部药物、激光小梁成形术和小梁切除术的年治疗费用与家庭年收入中位数(MA-HHI)的比值。结果显示,拉坦前列素、激光小梁成形术和小梁切除术在多个国家的费用达到或超过MA-HHI的2.5%,提示全球许多患者面临青光眼干预的经济负担。

要点

  • 噻吗洛尔是最可负担的药物,仅2国费用≥MA-HHI的2.5%。
  • 拉坦前列素在15国(41%)费用≥MA-HHI的2.5%,均为发展中国家。
  • 小梁切除术在28国(78%)费用≥MA-HHI的2.5%。

核心结论

  • 全球许多患者医疗、激光和切口手术干预费用达到或超过MA-HHI的2.5%,降低全球青光眼盲需提高干预可负担性。

研究设计与样本

  • 横断面观察性研究,从政府定价数据、药物数据库、医师费用表、学术出版物和与当地眼科医生沟通获取38个国家(17个发达国家、21个发展中国家)的青光眼干预价格。

主要发现

  • 噻吗洛尔费用范围为MA-HHI的0.1%至5%,拉坦前列素为0.1%至27%,激光小梁成形术为0.2%至17%,小梁切除术为0.3%至42%。
  • 噻吗洛尔在仅2国(5%)达到或超过MA-HHI的2.5%,拉坦前列素在15国(41%)达到或超过,其中15个发展中国家(75%)无发达国家。
  • 激光小梁成形术在15国(44%)达到或超过MA-HHI的2.5%,其中11个发展中国家(65%)和4个发达国家(24%)。
  • 小梁切除术在28国(78%)达到或超过MA-HHI的2.5%,其中18个发展中国家(95%)和10个发达国家(59%)。
  • 在18国(53%)中,激光小梁成形术费用低于3年拉坦前列素供应费用。

关键数值与推荐

  • 干预费用低于MA-HHI的2.5%视为可负担。
  • 价格经购买力平价和通胀调整至2016年美元。

临床怎么用

  • 临床选择青光眼干预时需考虑患者经济可负担性,尤其拉坦前列素和小梁切除术在部分国家费用较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Medical and surgical interventions for glaucoma are effective only if they are affordable to patients. Little is known about how affordable glaucoma interventions are in developing and developed countries. OBJECTIVE: To compare the prices of topical glaucoma medications, laser trabeculoplasty, and trabeculectomy relative with median annual household income (MA-HHI) for countries worldwide. DESIGN, SETTING AND PARTICIPANTS: Cross-sectional observational study. For each country, we obtained prices for glaucoma medications, laser trabeculoplasty, and trabeculectomy using government pricing data, drug databases, physician fee schedules, academic publications, and communications with local ophthalmologists. Prices were adjusted for purchasing power parity and inflation to 2016 US dollars, and annual therapy prices were examined relative to the MA-HHI. Interventions costing less than 2.5% of the MA-HHI were considered affordable. MAIN OUTCOMES AND MEASURES: Daily cost for topical glaucoma medications, cost of annual therapy with glaucoma medications, laser trabeculoplasty, and trabeculectomy relative to MA-HHI in each country. RESULTS: Data were obtained from 38 countries, including 17 developed countries and 21 developing countries, as classified by the World Economic Outlook. We observed considerable variability in intervention prices compared with MA-HHI across the countries and across interventions, ranging from 0.1% to 5% of MA-HHI for timolol, 0.1% to 27% for latanoprost, 0.2% to 17% for laser trabeculoplasty, and 0.3% to 42% for trabeculectomy. Timolol was the most affordable medication in all countries studied and was 2.5% or more of MA-HHI in only 2 countries (5%). The annual cost of latanoprost was 2.5% or more of MA-HHI in 15 countries (41%) (15 developing countries [75%] and no developed countries). The cost of laser trabeculoplasty was 2.5% or more of the MA-HHI in 15 countries (44%) (11 developing countries [65%] and 4 developed countries [24%]). The cost of trabeculectomy was 2.5% or more of the MA-HHI in 28 countries (78%) (18 developing countries [95%] and 10 developed countries [59%]). In 18 countries (53%), laser trabeculoplasty cost less than a 3-year latanoprost supply. CONCLUSIONS AND RELEVANCE: For many patients worldwide, the costs of medical, laser, and incisional surgical interventions were 2.5% or more of the MA-HHI. Successfully reducing global blindness from glaucoma requires addressing multiple contributing factors, including making glaucoma interventions more affordable.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zhao PY, Rahmathullah R, Stagg BC, et al. A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery. JAMA Ophthalmol. 2018. PMID: 30178000. doi:10.1001/jamaophthalmol.2018.3672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。